NKT cells - Conductors of tumor immunity?

Current Opinion in Immunology

Volumn 14, Issue 2, 2002, Pages 165-171

  Smyth, Mark J ^a   Crowe, Nadine Y ^b   Hayakawa, Yoshihiro ^a   Takeda, Kazuyoshi ^c   Yagita, Hideo ^c   Godfrey, Dale I ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 4;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL FUNCTION; CELL INTERACTION; CELL STIMULATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; METASTASIS INHIBITION; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR IMMUNITY;

EID: 0036533337     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(02)00316-3     Document Type: Review

References (60)

1. NKT cells: Facts, functions and fallacies
2. Mouse CD1-specific NK1 T cells: Development, specificity, and function
3. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice
4. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes
5. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells
6. NKT cells and tumor immunity - A double-edged sword
7. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
8. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes
9. Antitumor and antimetastatic activity of interleukin-12
10. + alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12
11. + alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis
12. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors
13. Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Vα14 NKT cells
14. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12
15. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
16. + alpha beta T cells in the lungs of euthymic and athymic mice
17. Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells
18. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12
19. The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent
20. + T cells in IL-12-induced immune responses in vivo
21. A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement
22. Antimetastatic effect of CpG DNA mediated by type I IFN
23. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice
24. Treatment of hepatic metastasis of the colon 26 adenocarcinoma with an alpha-galactosylceramide, KRN7000
25. Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells
26. Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver
27. KRN7000, a novel immunomodulator, and its antitumor activities
28. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells
29. Enhancing effects of (2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3, 4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells
30. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides
31. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution
32. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells
33. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways
34. + NKT cells: Stimulation of IL-12 production by antigen-presenting cells in the innate immune system
35. Requirement for IFN-gamma in IL-12 production induced by collaboration between V(alpha)14(+) NKT cells and antigen-presenting cells
36. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide
37. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers
38. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide
39. Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells
40. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells
41. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis
42. The interface between innate and acquired immunity: Glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes
43. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice
44. Sequential production of IFN-gamma by NKT cells and NK cells is essential for the anti-metastatic effect of alpha-galactosylceramide
45. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells
46. + NKT cells against melanoma
47. -αβ T cells and endogenous IL-4 in non-MHC-restricted rejection of embryonal carcinoma in genetically resistant mice
48. Differential tumor surveillance by natural killer (NK) and NKT cells
49. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
50. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway
51. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes
52. Immune suppression and skin cancer development: Regulation by NKT cells
53. Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population
54. + T cells upon NKR-P1 cross-linking
55. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: A pro-Th2 effect of IL-18 exerted through NKT cells
56. + T cells
57. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells
58. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells
59. MIP-2 recruits NKT cells to the spleen during tolerance induction
60. Inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide